PAPER Engeln M, Fasano S, Ahmed SH, Cador M, Baekelandt V, Bezard E, Fernagut PO
SEARCH RESULTS
330059 RESULTS
PAPER Goldman JG, Eichenseer SR, Berry-Kravis E, Zimnowodzki S, Gregory A, Hogarth P, Hayflick SJ
Clinical features of neurodegeneration with brain iron accumulation due to a C19orf12 gene mutation.
Mov Disord. 2013 Mar 13; PubMed: 23494994PAPER Forrest S, Chai A, Sanhueza M, Marescotti M, Parry K, Georgiev A, Sahota V, Mendez-Castro R, Pennetta G
Increased levels of phosphoinositides cause neurodegeneration in a Drosophila model of amyotrophic lateral sclerosis.
Hum Mol Genet. 2013 Mar 29; PubMed: 23492670PAPER Alvarez-Erviti L, Seow Y, Schapira AH, Rodriguez-Oroz MC, Obeso JA, Cooper JM
Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.
Cell Death Dis. 2013;4:e545. PubMed: 23492776PAPER Carare RO, Hawkes CA, Jeffrey M, Kalaria RN, Weller RO
Cerebral amyloid angiopathy, Prion angiopathy, CADASIL and the spectrum of Protein Elimination-Failure Angiopathies (PEFA) in neurodegenerative disease with a focus on therapy.
Neuropathol Appl Neurobiol. 2013 Mar 13; PubMed: 23489283PAPER Schellekens H, McNamara O, Dinan TG, McCarthy JV, McGlacken GP, Cryan JF
Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor.
J Pharm Pharmacol. 2013 Apr;65(4):528-38. PubMed: 23488781PAPER Dash SK
Cognitive impairment and diabetes.
Recent Pat Endocr Metab Immune Drug Discov. 2013 May;7(2):155-65. PubMed: 23489242PAPER Papaliagkas VT
The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?
Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. PubMed: 23489287PAPER Riudavets MA, Bartoloni L, Troncoso JC, Pletnikova O, St George-Hyslop P, Schultz M, Sevlever G, Allegri RF
Familial Dementia With Frontotemporal Features Associated With M146V Presenilin-1 Mutation.
Brain Pathol. 2013 Mar 14; PubMed: 23489366PAPER Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li QX, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL, AIBL research group
Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease.
Alzheimers Dement. 2014 Jan;10(1):53-61. Epub 2013 Mar 13 PubMed: 23491263PAPER Ryan J, Carrière I, Carcaillon L, Dartigues JF, Auriacombe S, Rouaud O, Berr C, Ritchie K, Scarabin PY, Ancelin ML
Estrogen receptor polymorphisms and incident dementia: The prospective 3C study.
Alzheimers Dement. 2013 Mar 9; PubMed: 23491264PAPER Khorram Khorshid HR, Manoochehri M, Nasehi L, Ohadi M, Rahgozar M, Kamali R
Ccr2-64i and Ccr5 Δ32 Polymorphisms in Patients with Late-Onset Alzheimer's disease; A Study from Iran (Ccr2-64i And Ccr5 Δ32 Polymorphisms in Alzheimer's disease).
Iran J Basic Med Sci. 2012 Jul;15(4):937-44. PubMed: 23493039PAPER Lahmy V, Meunier J, Malmström S, Naert G, Givalois L, Kim SH, Villard V, Vamvakides A, Maurice T
Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease.
Neuropsychopharmacology. 2013 Mar 14; PubMed: 23493042PAPER Aisen PS, Vellas B, Hampel H
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.
Nat Rev Drug Discov. 2013 Apr;12(4):324. PubMed: 23493086PAPER Sachdev PS, Zhuang L, Braidy N, Wen W
Is Alzheimer's a disease of the white matter?
Curr Opin Psychiatry. 2013 May;26(3):244-51. PubMed: 23493128Current Filters
No filters selected